Köhler G, Canzler E, Lembke S, Amon I, Ahrendt H J
Klinik und Poliklinik für Gynäkologie und Geburtshilfe, Bereichs Medizin der Ernst-Moritz-Arndt-Universität Greifswald.
Zentralbl Gynakol. 1987;109(21):1296-302.
Fifty eight fertile female volunteers between 20 to 45 years were enrolled in a clinical trial to evaluate the efficacy and tolerance of the progestin dienogest (17 alpha-cyanomethyl-17 beta-hydroxyestra-4,9-dien-3-one, VEB Jenapharm Jena GDR) as a postcoital contraceptive. An oral dose of 2 mg dienogest was administered immediately after each coitus. The 58 women reported 872 intercourses during 302 cycles. Frequency of ingestion was on average 3 times per cycle. Pregnancy occurred in 14 women corresponding to a Pearl-index of 55.6. The observed pregnancy rate referring to all intercourses was 1.6 per cent. The incidence of expected pregnancies in relation to the coital exposures was 4.04 per cent. As a result the risk of pregnancy was reduced 2.5 times by dienogest. Menstrual disorders occurred in 18.9 per cent in regard of the total numbers of cycles. The results and an overview of literature suggest that neither dienogest nor other progestins are suitable as a sole contraceptive method when used as a postcoital agent. They are only indicated as a risk-reducing method after so-called "contraceptive emergencies".
58名年龄在20至45岁之间的育龄女性志愿者参与了一项临床试验，以评估孕激素地诺孕素（17α-氰甲基-17β-羟基雌甾-4,9-二烯-3-酮，民主德国耶拿VEB Jenapharm公司生产）作为房事后避孕药的疗效和耐受性。每次性交后立即口服2毫克地诺孕素。这58名女性在302个周期内报告了872次性交。平均每个周期服药3次。14名女性怀孕，Pearl指数为55.6。所有性交的观察到的妊娠率为1.6%。与性交暴露相关的预期妊娠发生率为4.04%。结果表明，地诺孕素使怀孕风险降低了2.5倍。在所有周期中，18.9%出现了月经紊乱。结果以及文献综述表明，地诺孕素和其他孕激素作为房事后用药时，都不适合作为唯一的避孕方法。它们仅在所谓的“避孕紧急情况”后作为降低风险的方法使用。
